Media

November 12, 2021 | Publication
Lymph Node Targeted Boosting with Cognate Amphiphile-Peptide Vaccines Enhances TCR-T Cell Therapy to Eradicate Solid Tumors

Scientific Poster

November 12, 2021 | Publication
Drakes Dylan Lymph node targeted cognate amphiphile-peptide vaccines enhances tcr-t therapy

Audio recording

September 22, 2021 | Publication
Vaccination with a lymph node targeted Amphiphile‐CpG adjuvant promotes potent cellular and humoral immunity to SARS‐CoV‐2 protein subunit antigens

Peter DeMuth, PhD, Vice President of Research — Vaccines Summit 2021

September 9, 2021 | Publication
Approaches to Improve the Clinical Performance of Genetically Engineered T Cells
July 10, 2021 | Publication
Combined PET and Whole Tissue Imaging of Lymphatic Targeting vaccine in NHPs

Antigen accumulation in lymph nodes (LNs) is critical for vaccine efficacy, but understanding of vaccine biodistributionin humans or large animals remains limited.

March 19, 2021 | Publication
Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells

Tissue-resident memory T cells (TRMs) can profoundly enhance mucosal immunity, but parameters governing TRM induction by vaccination remain poorly understood.

February 2, 2021 | Publication
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Science Advances Martin P. Steinbuck, Lochana M. Seenappa, Aniela Jakubowski, Lisa K. McNeil, Christopher M. Haqq*, Peter C. DeMuth The profound consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mandate urgent development of effective vaccines. Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid–modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor […]

October 2, 2020 | Publication
World Vaccine Congress: A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

The SARS-CoV-2 pandemic’s public health, economic, and social impacts mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain (Spike RBD) protein for immunization (ELI 005).

September 15, 2020 | Publication
RAS Summit: Targeting the lymph nodes to enhance mutant KRAS-specific vaccine responses
August 18, 2020 | Publication
A lymph node targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

The SARS-CoV-2 pandemic has led to public health, economic, and social consequences that mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) […]